GoodLifeStudio/E+ by way of Getty Photos
- The U.S. FDA granted approval to Evolus’ (NASDAQ:EOLS) Evolysse Type and Clean hyaluronic gels.
- The corporate plans to launch the merchandise in Q2.
- “The launch of those merchandise is a catalyst in our development as we’re targeted on attaining a minimum of $700 million in internet income and non-GAAP working earnings margin of a minimum of 20% by 2028,” CEO David Moatazedi stated in a information launch.